Core Viewpoint - Idorsia Ltd has successfully completed a repurchase offer for its convertible bonds, significantly reducing its outstanding debt and restructuring its financial obligations [1][4]. Group 1: Repurchase Offer Details - The repurchase offer for the CHF 204 million convertible bonds maturing in 2025 (CB 2025) saw bondholders accept an aggregate nominal value of CHF 187,476,000, which is 91.90% of the total issued nominal value [2]. - For the CHF 600 million convertible bonds maturing in 2028 (CB 2028), bondholders accepted an aggregate nominal value of CHF 567,200,000, corresponding to 94.53% of the total issued nominal value [2]. - The settlement involved the issuance of A1 Notes (CHF 120,037,805), A2 Notes (CHF 254,962,195), and B Notes (CHF 379,676,000), along with 8,040,000 Exchange Shares and 8,040,000 Exchange Warrants [3]. Group 2: Financial Restructuring - The completion of the repurchase offer is part of a broader restructuring plan agreed upon with a majority of bondholders, initially announced on February 26, 2025 [4]. - A total nominal value of CHF 761,779,000 in A1, A2, and B Notes has been issued by Idorsia Investments SARL as part of this restructuring [4]. - The company plans to establish an equity line for up to 20,000,000 shares, set to expire at the end of February 2026, to extend its cash runway into 2027 [5]. Group 3: Company Overview - Idorsia aims to challenge established medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [6]. - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs, with a promising in-house development pipeline [7]. - Idorsia is listed on the SIX Swiss Exchange under the ticker symbol IDIA [8].

Core Points - Idorsia Ltd has announced the results of its repurchase offer for outstanding convertible bonds totaling CHF 204 million maturing in 2025 and CHF 600 million maturing in 2028 [1][2] - The repurchase offer for the 2025 bonds saw an acceptance rate of 91.90%, with bondholders accepting an aggregate nominal value of CHF 187,476,000, while the 2028 bonds had a 94.53% acceptance rate with CHF 567,200,000 accepted [2] - The settlement of the repurchase offer is expected to occur on August 26, 2025, pending the satisfaction or waiver of certain conditions [3] Company Overview - Idorsia aims to challenge established medical paradigms by discovering, developing, and commercializing transformative medicines, evolving into a leading biopharmaceutical company [5] - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs, with a promising in-house development pipeline and partnerships to enhance portfolio value [6]

Core Viewpoint - Idorsia Ltd has successfully completed a repurchase offer for its convertible bonds, with significant acceptance rates from bondholders for both the 2025 and 2028 bonds [1][2]. Group 1: Repurchase Offer Details - The repurchase offer was launched on June 25, 2025, for CHF 204 million convertible bonds maturing in 2025 and CHF 600 million convertible bonds maturing in 2028 [1]. - As of the end of the additional acceptance period, bondholders accepted the repurchase offer for the CB 2025 with an aggregate nominal value of CHF 187,476,000, which is 91.90% of the total issued nominal value [2]. - For the CB 2028, bondholders accepted the offer with an aggregate nominal value of CHF 567,200,000, corresponding to 94.53% of the total issued nominal value [2]. Group 2: Settlement and Documentation - The settlement of the repurchase offer is expected to occur on August 26, 2025, pending the satisfaction or waiver of certain offer conditions [3]. - Additional information regarding the repurchase offer and related documentation can be found on Idorsia's official website [3]. Group 3: Company Overview - Idorsia aims to challenge accepted medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [5]. - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs that can change treatment paradigms for various patients [6].

Core Points - Idorsia Ltd has announced interim results for its repurchase offer of outstanding convertible bonds totaling CHF 204 million maturing in 2025 and CHF 600 million maturing in 2028, launched on June 25, 2025 [1][2] - The acceptance rates for the repurchase offer were significantly high, with 90.88% of the CB 2025 and 93.63% of the CB 2028 bonds accepted, surpassing the minimum acceptance rate of 85% [2] - An additional acceptance period for the repurchase offer will take place from August 12 to August 18, 2025, with settlement expected around August 26, 2025 [3] Company Overview - Idorsia aims to challenge established medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [5] - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs, with a promising in-house development pipeline and partnerships to enhance portfolio value [6]

Core Viewpoint - Idorsia Ltd. successfully held bondholder meetings to approve amendments to the terms of its convertible bonds, extending their maturity dates significantly [1][2][3]. Group 1: Bondholder Meetings - Two bondholder meetings were conducted for Idorsia's CHF 200 million convertible bonds maturing in 2025 and CHF 600 million convertible bonds maturing in 2028 [2]. - The amendments include extending the maturity date of the CB 2025 to July 17, 2034, and the CB 2028 to August 4, 2038 [2]. Group 2: Voting Outcomes - A significant majority of 89.5% of CB 2025 holders and 93.5% of CB 2028 holders voted in favor of the amendments, surpassing the required two-thirds majority [3]. - The amendments will become binding upon approval by the higher cantonal composition authority and are contingent on the completion of the repurchase offer for both bonds [3]. Group 3: Company Overview - Idorsia Ltd. aims to challenge medical paradigms and develop transformative medicines, positioning itself as a leading biopharmaceutical company [6]. - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drug discovery [7].

Core Viewpoint - Idorsia Ltd has announced a repurchase offer for its outstanding convertible bonds as part of a broader restructuring strategy aimed at enhancing its financial position and operational efficiency [1][2]. Group 1: Repurchase Offer Details - The repurchase offer targets CHF 200 million convertible bonds maturing in 2025 and CHF 600 million convertible bonds maturing in 2028 [1]. - Approximately 87.5% of the CB 2025 and 90.1% of the CB 2028 bondholders have entered into a lockup agreement to support the restructuring and participate in the repurchase offer [3]. - The main offer period for the repurchase is set to begin on July 10, 2025, and conclude on August 7, 2025, with a minimum acceptance condition of 85% of the total issued nominal value required for the offer to proceed [4]. Group 2: Participation and Documentation - Bondholders can access the repurchase offer documentation and participate through Kroll Issuer Services Ltd, which will also facilitate a new money facility for eligible bondholders [5]. - Detailed instructions and eligibility criteria for participation in both the repurchase offer and the new money facility are available in the repurchase offer documentation [5]. Group 3: Company Overview - Idorsia Ltd aims to challenge established medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [7]. - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs, with a promising development pipeline and partnerships to maximize portfolio value [8].

Core Viewpoint - Idorsia Ltd is conducting bondholder meetings on June 25, 2025, to vote on proposed amendments to the terms of its outstanding convertible bonds, CB 2025 and CB 2028, as part of a holistic restructuring plan [1][2][3]. Group 1: Bondholder Meetings - The bondholder meetings are scheduled for June 25, 2025, to discuss amendments to the terms of the CHF 200 million convertible bonds maturing in 2025 (CB 2025) and CHF 600 million convertible bonds maturing in 2028 (CB 2028) [2][3]. - Approximately 87% of CB 2025 holders and 90% of CB 2028 holders have entered legally binding lockup agreements in support of the restructuring, committing to vote in favor of the proposed amendments [4]. Group 2: Restructuring and Conditions - The proposed amendments to the terms of CB 2025 and CB 2028 are part of a larger holistic restructuring plan announced earlier in 2025 [3]. - The amendment of the terms will be contingent upon the successful completion of an exchange offer expected to be launched around the time of the bondholder meetings [5]. Group 3: Company Overview - Idorsia Ltd aims to challenge accepted medical paradigms and is focused on discovering, developing, and commercializing transformative medicines [8]. - The company is headquartered near Basel, Switzerland, and has a strong scientific core with a promising in-house development pipeline [9].

Core Viewpoint - Idorsia Ltd held its Annual General Meeting (AGM) where shareholders overwhelmingly supported all proposals from the Board of Directors, indicating strong confidence in the company's future direction and leadership [1][2]. Corporate Governance - The AGM was attended by 166 shareholders representing 97,748,740 shares, which is 43.28% of the total outstanding shares [1]. - Shareholders approved the re-election of all Board members for a term until the conclusion of the AGM 2026, including Jean-Paul Clozel as Chairman [4]. - The company granted discharge to all members of the Board of Directors and the Executive Committee for the financial year 2024 [3]. Financial Performance - Shareholders approved the Annual Report 2024, the Consolidated Financial Statements 2024, and the Statutory Financial Statements 2024 [2]. - The appropriation of available earnings was approved, with the net loss for the year 2024 to be carried forward [3]. Compensation and Audit - The aggregate maximum amount of compensation for the Board of Directors and the Executive Committee for the upcoming terms was approved [5]. - Deloitte AG was re-elected as the statutory auditors for the financial year 2025 [6]. Company Vision and Strategy - Idorsia aims to challenge accepted medical paradigms and is focused on discovering, developing, and commercializing transformative medicines [8]. - The company is positioned to become a leading biopharmaceutical entity in Europe, leveraging its strong scientific core and promising development pipeline [9].

Core Points - Idorsia Ltd has announced the date for its Annual General Meeting (AGM) to be held on May 28, 2025, to approve the Annual Report for the year ending December 31, 2024 [1] - The Chairman of the Board, Jean-Paul Clozel, expressed gratitude towards the Board members and noted that Dr. Sophie Kornowski will not seek re-election, while all other members will stand for re-election [2] - The company aims to amend its Articles of Association regarding share capital to enhance financing flexibility [2] Company Overview - Idorsia Ltd is focused on discovering, developing, and commercializing transformative medicines, with a strong scientific core and a commitment to challenging accepted medical paradigms [6][8] - The company is headquartered near Basel, Switzerland, and is positioned within a European biotech hub, emphasizing its capabilities in drug discovery, particularly in small-molecule drugs [7][8] AGM Agenda Highlights - The AGM will include votes on the Annual Report 2024, Consolidated Financial Statements 2024, and Statutory Financial Statements 2024 [7] - Other key agenda items include the appropriation of available earnings, discharge of the Board of Directors, amendments to share capital, and re-elections of Board members and statutory auditors [7]